

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

INSIDE INFORMATION THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated October 25, 2024 and March 14, 2025 in relation to the proposed participation in the H share full circulation programme by the Company and the issuance of filing notice by CSRC regarding the implementation of the H share full circulation of the Company (the “**Announcements**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The Company has applied to the Listing Committee of the Stock Exchange for the approval of the listing of and permission to deal in 14,114,006 H Shares (the “**Converted H Shares**”) on the Main Board of the Stock Exchange (the “**Conversion and Listing**”), representing the maximum number of the Unlisted Shares entitled to be converted according to the Filing Notice. The Company is pleased to announce that the listing approval was granted by the Stock Exchange on April 24, 2025 (the “**Listing Approval**”).

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve a total of 7 participating shareholders (the “**Participating Shareholders**”) of 14,114,006 Unlisted Shares to be converted, who will, after the Conversion and Listing, hold approximately 3.56% of the total issued H Shares. Set out below is the percentage holding of the Participating Shareholders upon completion of the Conversion and Listing.

No.	Name of the Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued H Shares upon completion of the Conversion and Listing
1.	Gongqing City Ruiji Fund III Investment Partnership (共青城瑞吉三期投資合夥企業(有限合夥))	3,463,672	0.87%
2.	Sunshine Life Insurance Corporation Limited (陽光人壽保險股份有限公司)	3,350,655	0.85%
3.	Shengzhou Minglang Industry Development Equity Investment Fund Partnership (Limited Partnership) (嵊州市銘朗產業發展股權投資基金合夥企業(有限合夥))	2,633,332	0.66%
4.	Shanghai Sci-Tech Innovation Center Capital Fund I (Limited Partnership) (上海科創中心壹號股權投資基金合夥企業(有限合夥))	1,066,815	0.27%
5.	Nanjing Xingjian Ruiying Equity Investment Partnership (Limited Partnership) (南京星健睿贏股權投資合夥企業(有限合夥))	1,697,445	0.43%
6.	Gongqing City Chuangdongfang Huaying Equity Investment Partnership (Limited Partnership) (共青城創東方華盈股權投資合夥企業(有限合夥))	1,227,717	0.31%
7.	Wuhu Bloomage Langya Healthcare Industry Investment Partnership (Limited Partnership) (蕪湖華熙朗亞健康產業投資合夥企業(有限合夥))	674,370	0.17%
Total		14,114,006	3.56%

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Description of Shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	<i>Number of Shares</i>	<i>Approximate percentage</i>	<i>Number of Shares</i>	<i>Approximate percentage</i>
Unlisted Shares	25,144,396	6.17%	11,030,390	2.71%
H Shares	382,163,299	93.83%	396,277,305	97.29%
Total	<u>407,307,695</u>	<u>100.00%</u>	<u>407,307,695</u>	<u>100.00%</u>

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in compliance with the requirements under the Listing Rules and the applicable laws, as and when appropriate.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
 宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Hong Kong, April 24, 2025

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.